Benefits and risks of FDA‐approved amyloid‐targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician‐patient engagement

Documenti analoghi

• Deployment and transcriptional evaluation of nitisinone, an FDA ‐approved drug, to control bed bugs
  di: Marcos Sterkel, et al.
  Pubblicazione: (2025)
• Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
  di: Ronald C. Petersen, et al.
  Pubblicazione: (2025)
• Identifying differentially expressed proteins between amyloid positive and amyloid negative subjects based on Alamar multiplex assay data using MissionAD samples
  di: Pallavi Sachdev, et al.
  Pubblicazione: (2025)
• The Alzheimer’s Tau Platform (ATP): a Phase 2, combination amyloid and tau therapy clinical trial for early AD
  di: Adam L. Boxer, et al.
  Pubblicazione: (2024)
• FDA approves capivasertib with fulvestrant for breast cancer
  di: Mary Beth Nierengarten
  Pubblicazione: (2024)